Caliway Biopharmaceuticals

6919

The current Caliway Biopharmaceuticals (6919) market capitalization is approximately NT$240.39B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Caliway Biopharmaceuticals's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:19 AM Eastern Time

In the most recently reported quarter, Caliway Biopharmaceuticals (6919) generated NT$13.42M in revenue, representing a -42.32% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately NT$12.00M, implying an expected +28.16% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 4:24 AM Eastern Time

In the most recently reported fiscal year, Caliway Biopharmaceuticals (6919) generated net income of NT$-0.59B, compared with NT$-0.49B in the prior fiscal year, representing a -20.55% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of NT$-0.69B. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 4:24 AM Eastern Time

According to its latest quarterly filing, Caliway Biopharmaceuticals (6919) reported EBITDA of NT$-0.20B, representing a -32.62% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 4:24 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.00x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 4:24 AM Eastern Time

Based on the latest available data, Caliway Biopharmaceuticals (6919) is currently trading at a last twelve months (LTM) P/E ratio of -267.24x. Looking forward, the stock trades at a next twelve months (NTM) P/E ratio of 64.85x, based on consensus earnings estimates. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 4:24 AM Eastern Time

In the most recently reported quarter, Caliway Biopharmaceuticals (6919) revenue was NT$13.42M, compared with analyst consensus expectations of NT$8.00M, representing a +67.69% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were NT$-0.01, compared with consensus estimates of NT$-0.19, resulting in an +94.74% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 4:24 AM Eastern Time

Caliway Biopharmaceuticals (6919) does not currently pay a dividend. Over the last twelve months (LTM), the company paid NT$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 4:24 AM Eastern Time

Analyst assessments of whether Caliway Biopharmaceuticals (6919) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: NT$155.00Consensus price target: NT$240.00Implied return: +54.84% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 4:24 AM Eastern Time

Based on the latest available analyst coverage, Caliway Biopharmaceuticals (6919) currently carries a Buy consensus rating. Analysts' average 6919 price target is NT$240.00. Relative to the current share price of NT$155.00, this suggests a potential price change of approximately +54.84%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 4:24 AM Eastern Time

Like other publicly traded stocks, Caliway Biopharmaceuticals (6919) shares are bought and sold on stock exchanges such as TWSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Caliway Biopharmaceuticals (6919) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 6919 to your watchlist.

Caliway Biopharmaceuticals trades under the ticker symbol 6919 on the TWSE stock exchange. The ticker 6919 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

Caliway Biopharmaceuticals (6919) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Caliway Biopharmaceuticals (6919) stock peers based on overlapping products, services, and competitive dynamics:Regent Pacific Group (575)Percheron Therapeutics (PER)Neurizon Therapeutics (NUZ)Klaria Pharma Holding AB (publ.) (KLAR)SoftOx Solutions AS (SOFTX) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Caliway Biopharmaceuticals.